News FDA orders blindness risk warning to GLP-1 agonist labels FDA has ordered all GLP-1 receptor agonist manufacturers to add a warning to their product labels for a rare eye condition that can cause blindness.
News Novo Nordisk's IL-6 drug flunks two more heart trials Novo Nordisk has opted to discontinue two late-stage trials of IL-6 inhibitor ziltivekimab in heart failure, after taking an interim look at the data.
News Novo Nordisk wins Netherlands GLP-1 compounding lawsuit A Dutch compounding pharmacy has been ordered to stop distributing a compounded nasal spray version of Novo Nordisk's GLP-1 agonist semaglutide.
News Generic semaglutide in India, and other weight-loss news Novo Nordisk is facing generic semaglutide in India, Atrogi is testing a new weight loss approach, and Structure has more data with its oral GLP-1.
News Novo partners with Hims & Hers again, ending GLP-1 spat Novo Nordisk and Hims & Hers have set their differences aside, agreeing to work together once again on the sale of GLP-1 agonists.
News Novo Nordisk rises as Hims & Hers backs down on oral GLP-1 Novo Nordisk's battered stock enjoyed a reprieve after Hims & Hers abandoned plans to launch a compounded version of the new Wegovy pill.
Patients Patients not just at the table, but creating their own: In c... Donna Cryer, founding partner and Chief Patient Officer of CryerHealth, LLC discusses why is patient inclusion is not the same as patient leadership.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.